HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Providing High Value, OTC Drugs Deserve Higher Profile In Health Care – CHPA

Executive Summary

While Rx drug pricing is under attack by Congress, White House and consumer and public health advocacy groups, OTC drugs' value isn't gaining a higher profile. "Our health care system undervalues the contribution of our industry's products," says CHPA chief Scott Melville. Trade group conducts “Value of OTC Medicines" study for reasons including raising the profile of consumer health products in the US health care system.

You may also be interested in...



Health And Wellness Industry News: Restoring Access Bill Introduced, Another Dietary Fiber Meets FDA Definition, More

Restoring Access to OTC bill introduced; West Virginia is 18th state to prohibit sales of DXM-containing cough suppressant to minors without a prescription; American Botanical Council presents Norman R. Farnsworth Excellence Award to Swiss pharmacist Otto Sticher; FDA adds another fiber to definition of dietary fiber; and Jarrow probiotics top ConsumerLab brand survey.

CHPA Eyes Spanning Self-Care Space With Bridge To Device Sector

Many CHPA members also market medical devices "and the consumer side of medical devices is something they feel is underrepresented by other trade associations,” says trade group head Scott Melville. OTC drugs already have “a lot in common” with consumer medical devices, including that paying for neither typically is included in health insurance plans.

Gottlieb An Anchor For OTC Drug Industry On Stormy Congressional Seas

Commissioner Gottlieb has been a “very strong champion” of FDA and his interest in improving the OTC monograph and switch processes provides hope to the industry during a tumultuous legislative era, say CHPA executives at their annual meeting in Florida. They expect monograph reform will happen this year but doubt much else will happen before mid-term elections in November.

Related Content

Topics

UsernamePublicRestriction

Register

RS148637

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel